NPJ Breast Cancer

Share this on social media:

Nature Publishing Group is joining forces with the Breast Cancer Research Foundation (BCRF) to publish npj Breast Cancer, an open access research journal which will help us to understand, prevent, treat and cure the world’s second most common cancer.

NPJ Breast Cancer will publish high quality research that is online-only, and free to access, enabling academics, clinicians and patients to stay up to date with the latest research on the subject. The journal will publish original research articles, reviews, editorials, commentaries, and hypothesis on all areas of breast cancer research.

'Our collaboration with the Nature Publishing Group will provide BCRF an exceptional opportunity to serve the scientific community and the general public in several ways,' said Larry Norton, MD - BCRF Scientific Director and Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center. 'With npj Breast Cancer, we plan not only to report important new findings in breast cancer research but also to capture the creativity, controversy, and deep thought intrinsic to the process.'

Martin Delahunty, global head of Nature Partner Journals at NPG, said: 'NPJ Breast Cancer will publish the most advanced, multi-disciplinary and game changing research in its field, aided by our exclusive partnership with the Breast Cancer Foundation who have raised over US$500 million to support clinical and translational research at medical institutions worldwide. Because content is free to access along with lay editorial summaries, clinicians, patients and their families will benefit from the published work without need for a subscription.'

Dr. Norton and Dr. Clifford A. Hudis, MD, chairman of the BCRF Scientific Advisory Board and chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, are the joint editors in chief for NPJ Breast Cancer.  Both Dr. Norton and Dr. Hudis are past presidents of the American Society of Clinical Oncology (ASCO).

Topics covered will include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies, carcinogenesis, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and perturbation, and studies of the tumour microenvironment.